These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6211231)

  • 1. Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors.
    Silver BA; Barlock AL; Lippman ME; Anderson T; Fisher RI
    Cancer Treat Rep; 1982 May; 66(5):1229-30. PubMed ID: 6211231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of chlorozotocin.
    Gralla RJ; Tan CT; Young CW
    Cancer Treat Rep; 1979 Jan; 63(1):17-20. PubMed ID: 154363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of chlorozotocin in malignant melanoma: a Southeastern Cancer Study Group report.
    Van Amburg AL; Presant CA; Burns D
    Cancer Treat Rep; 1982 Jun; 66(6):1431-3. PubMed ID: 6211234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group Study.
    Ahmann FR; Meyskens FL; Jones SE; Bukowski RM; Saiers JH; Ryan DH; Costanzi J; Vaughn CB; Coltman CA
    Cancer Treat Rep; 1983; 67(7-8):697-700. PubMed ID: 6688199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of maytansine and chlorozotocin in patients with disseminated malignant melanoma.
    Ahmann DL; Frytak S; Kvols LK; Hahn RG; Edmonson JH; Bisel HF; Creagan ET
    Cancer Treat Rep; 1980; 64(4-5):721-3. PubMed ID: 6448689
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II study of chlorozotocin in advanced breast cancer.
    Edmonson JH; Green SJ; Ingle JN; Ahmann DL; Disel HF; Creagan ET
    Cancer Treat Rep; 1981; 65(5-6):537-8. PubMed ID: 6453648
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of advanced soft tissue sarcoma with chlorozotocin: a phase II trial of the EORTC soft tissue and bone sarcoma group.
    Mouridsen HT; Bramwell VH; Lacave J; Metz R; Vendrik C; Hild J; McCreanney J; Sylvester R
    Cancer Treat Rep; 1981; 65(5-6):509-11. PubMed ID: 6453646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary results of a phase II trial on solid tumors of detorubicin, a new anthracyclin.
    Cancer Clin Trials; 1980; 3(2):115-20. PubMed ID: 7428135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of vindesine in the treatment of lymphomas, breast cancer, and other solid tumors.
    Miller TP; Jones SE; Chester A
    Cancer Treat Rep; 1980; 64(8-9):1001-3. PubMed ID: 7448818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Phase I-II studies of a new antineoplastic agent, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA)].
    Horikoshi N; Ogawa M; Inagaki J; Ezaki K; Inoue K; Okabe K; Nagata T; Aiba K; Domyo M
    Gan To Kagaku Ryoho; 1982 Feb; 9(2):244-9. PubMed ID: 6897858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578).
    Creech RH; Stanley K; Vogl SE; Ettinger DS; Bonomi PD; Salazar O
    Cancer Treat Rep; 1982 Jun; 66(6):1417-9. PubMed ID: 6282460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II evaluation of chlorozotocin in patients with malignant melanoma.
    Houghton AN; Camacho FJ; Gralla RJ; Wittes R
    Cancer Treat Rep; 1981; 65(7-8):705-6. PubMed ID: 6454487
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II study of chlorozotocin in the treatment of advanced colorectal cancer.
    Lawton JO; Giles GR; Hall J; MacAdam A; Hall R; Matheson T; Bird G
    Cancer Treat Rep; 1981; 65(1-2):13-15. PubMed ID: 6452945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical drug development: an analysis of phase II trials, 1970-1985.
    Marsoni S; Hoth D; Simon R; Leyland-Jones B; De Rosa M; Wittes RE
    Cancer Treat Rep; 1987 Jan; 71(1):71-80. PubMed ID: 3791270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
    Alberts DS; Mackel C; Pocelinko R; Salmon SE
    Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial of chlorozotocin, DTIC, and dactinomycin in metastatic malignant melanoma.
    Samson MK; Baker LH; Cummings G; Talley RW; McDonald B; Bhathena DB
    Cancer Treat Rep; 1982 Feb; 66(2):371-3. PubMed ID: 6459845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chlorozotocin: phase II evaluation in patients with advanced sarcomas.
    Sordillo PP; Magill GB; Gralla RJ
    Cancer Treat Rep; 1981; 65(5-6):513-4. PubMed ID: 6453647
    [No Abstract]   [Full Text] [Related]  

  • 18. Broad phase II study of vindesine.
    Valdivieso M; Bedikian AY; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1981; 65(9-10):877-9. PubMed ID: 7273021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval.
    Goffin J; Baral S; Tu D; Nomikos D; Seymour L
    Clin Cancer Res; 2005 Aug; 11(16):5928-34. PubMed ID: 16115935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phase II study of mitoxantrone].
    Tada A; Ogawa M; Usui N; Inagaki J; Horikoshi N; Inoue K; Ikeda K; Adachi K; Nakada H; Okada Y
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1649-54. PubMed ID: 6476838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.